[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rhematoid-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rhematoid-arthritis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,79,100,127,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100633997","phase-1-a-phase-1-study-of-jade201-in-participants-with-rheumatoid-arthritis-100633997",false,"NCT07533955","A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis","A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JADE201 Administered Subcutaneously in Participants With Rheumatoid Arthritis","Inclusion Criteria:\n\n1. Male and female participants 18-70 years of age, inclusive.\n2. A body weight between 50-100 kg and a body mass index (BMI) between 18-32 kg\u002Fm2 (all inclusive) at screening.\n3. Confirmed diagnosis of RA according to 2010 ACR\u002FEULAR criteria\n4. Willing and able to comply with the inpatient stay at the site, scheduled visits, treatment plans, laboratory tests, and other study procedures specified in the protocol.\n5. Willing and able to comply with contraceptive and lifestyle requirements specified in the protocol.\n\nExclusion Criteria:\n\n1. With the exception of RA, known history of clinically significant disease\n2. Diagnosis or symptoms suggestive of any systemic autoimmune or inflammatory condition other than RA\n3. positive serology for Hep A, Hep B, or Hep C virus\n4. Positive, indeterminate, or invalid test of TB\n5. Current tobacco users who smoke \\>5 cigarettes per day or equivalent\n6. Nursing, lactating or pregnant, or who have plans to become pregnant during the study\n7. Treatment with an investigational drug within 30 days or 5 half lives prior to study drug administration","ALL","18 Years","70 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a Phase 1, first in human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE201 compared to placebo in participants with Rheumatoid Arthritis",[27],"Rhematoid Arthritis","RECRUITING","2026-05-27",{"date":31,"type":32},"2026-06-01","ACTUAL",{"date":34,"type":32},"2026-05-19",{"date":36,"type":21},"2028-10",{"name":38,"class":39},"Jade Biosciences, Inc.","INDUSTRY",3,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100626410","kinesiophobia-in-rheumatoid-arthritis-associations-with-functional-disability-disease-activity-and-related-clinical-factors-100626410","NCT07435272","Kinesiophobia in Rheumatoid Arthritis: Associations With Functional Disability, Disease Activity, and Related Clinical Factors","Inclusion Criteria:\n\n* Age: adult population with RA (18-69)\n* Disease duration ≥ 6 months\n\nExclusion Criteria:\n\n1. Juvenile cases\n2. Other rheumatic diseases (SLE, AS, 1ry OA, etc.)\n3. Trauma\n4. Comorbidities that affect mobility, e.g., UMNL (including stroke), parkinsonism, multiple sclerosis, cerebral palsy, dementia, peripheral neuropathy, chronic pain conditions, etc.\n5. Previous history of psychiatric illness before onset of RA (anxiety, depression, etc.)\n6. Pregnancy and lactation",true,"69 Years",{"count":50,"type":21},400,"OBSERVATIONAL","Objectives: Impairment of physical function is a core feature of RA, particularly in patients with high disease activity where pain and inflammation directly limit movement. but, Reduced mobility in RA is not exclusively driven by inflammatory pathology. There are non-inflammatory factors, including kinesiophobia, fatigue, depression, and anxiety, may significantly contribute to functional limitation and may initiate a self-perpetuating cycle in which movement avoidance leads to physical deconditioning, muscle weakness, and progressive functional decline. The aim of this study is to examine the relationship between kinesiophobia and functional outcomes in patients with rheumatoid arthritis, and to investigate its associations with disease activity, pain, fatigue, depressive symptoms, anxiety, and sarcopenia, with a focus on factors relevant to functional assessment and rehabilitation.\n\nPatients and Methods\n\nA case - control study will be conducted on Two hundred adult patients previously diagnosed with RA according to ACR\u002FEULAR 2010 criteria for RA and 200 apparently healthy volunteers with age and sex matching will be involved in the study. The study will be conducted in Rheumatology department, Minia university Hospital, Egypt. All patients will be subjected to history taking, clinical examination, and assessment of the following parameters:\n\n1. Kinesiophobia: using the Arabic version of TSK-17\n2. Disease activity: using DAS 28\n3. pain severity using the Visual Analogue Scale (VAS)\n4. Fatigue: using the Arabic version of the Fatigue Severity Scale (FSS)\n5. Depression: using the Arabic version of the BDI-2\n6. Anxiety: using the Arabic version of the BAI\n7. sarcopenia using the Arabic version of the SARC-F questionnaire\n8. Functional disability: using the Arabic version of the HAQ-DI\n9. Physical activity:using IPAQ-SF",[54,27,55,56],"Kinesiophobia (Fear of Movement)","Rheumatoid Arthritis (RA)","Rheumatoid",[58,59,60,61,62,63,64,65,66,67],"Kinesiophobia","Fear of Movement","Rheumatoid Arthritis","Functional Disability","Disease Activity","Pain","Fatigue","Anxiety","Depression","sarcopenia","NOT_YET_RECRUITING","2026-02-27",{"date":71,"type":32},"2026-03-03",{"date":73,"type":21},"2026-03-01",{"date":75,"type":21},"2026-10-01",{"name":77,"class":78},"Minia University","OTHER",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100623523","evaluation-of-ccr6-gene-expression-and-circulating-ccl20-levels-as-potential-biomarkers-in-rheumatoid-arthritis-100623523","NCT07397741","Evaluation of CCR6 Gene Expression and Circulating CCL20 Levels as Potential Biomarkers in Rheumatoid Arthritis","Inclusion Criteria:\n\n* Adults (18-60 years) diagnosed with RA according to the American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR) 2010 classification criteria for RA by an expert rheumatologist.\n\nExclusion Criteria:\n\n* • Patients with co-existing infections or other autoimmune diseases.","60 Years",{"count":87,"type":21},60,"Rheumatoid arthritis (RA) is characterized as a systemic auto immune disorder linked to a persistent inflammatory process that can harm both joints and extra articular organs.\n\nThe upregulation of the CCR6\u002FCCL20 axis in the synovial tissues and salivary glands (in cases of secondary Sjögren's syndrome) is considered to contribute to the recruitment of Th17 cells, which in turn enhances IL 17A production and promotes the inflammatory cycle.",[27],[91],"CCR6\u002FCCL20 axis in Rheumatoid arthritis","2026-02-05",{"date":94,"type":32},"2026-02-09",{"date":73,"type":21},{"date":97,"type":21},"2027-03-01",{"name":99,"class":78},"Sohag University",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":111,"studyType":51,"phases":4,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100622806","pharmacogenetics-of-leflunomide-in-the-management-of-rheumatoid-arthritis-100622806","NCT07388407","Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis","Pharmacogenetics of Leflunomide in the RA Management","Inclusion Criteria:\n\n* At baseline, all patients should fulfill the revised ACR\u002FEULAR criteria for RA10\n* Pakistani individuals\n* between ages of 20-75 years\n* New cases started on Leflunomide\u002F those already taking for less than a month and their biochemical and clinical data is available\n\nExclusion Criteria:\n\n* Patients not willing to participate\u002F consent not given\n* Patients below the age of 20\n* Non- Pakistani origin\n* Taking another DMARD simultaneously\n* Compromised renal and hepatic functions\n* Cognitive impairment, neurological disease\n* Pregnant\u002F lactating patients\n* Patients having inflammatory bowel disease\u002F Irritable bowel syndrome\n* Patients with active infective diseases -Patients who fail to complete 3 months of leflunomide therapy-","20 Years","65 Years",{"count":110,"type":21},110,"2 Months","1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent.\n2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity will be filled.\n3. DNA will be extracted in the laboratory, and SNP will be identified.\n4. The efficacy and toxicity data will be studied against the SNPs found\n5. An algorithm will be constructed for Pakistani RA patients taking leflunomide.",[27],[115,116,117],"RA","SNP","Leflunomide","2026-01-30",{"date":92,"type":32},{"date":121,"type":32},"2024-09-01",{"date":123,"type":21},"2026-09-30",{"name":125,"class":78},"Foundation University Islamabad",2,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100612337","phase-4-very-low-dose-prednisolone-on-newly-diagnosed-rheumatoid-arthritis-100612337","NCT07252271","Very Low Dose Prednisolone on Newly Diagnosed Rheumatoid Arthritis","Very Low Dose, add-on Prednisolone in Patients With Newly Diagnosed Rheumatoid Arthritis: a Randomised Placebo-controlled Study","Inclusion Criteria:\n\n1. ≥18 year-old\n2. Fulfilment of the 2010 ACR\u002FEULAR classification criteria of RA\n3. Never use of any DMARDs for RA -\n\nExclusion Criteria:\n\n1. Pregnancy or premenopausal women planning pregnancy\n2. Functional status class IV (limited in ability to perform usual self-care, vocational, and avocational activities)\n3. Use of systemic GC in recent one month\n4. Contraindications to prednisolone",{"count":135,"type":21},112,[137],"PHASE4","Objective To investigate the efficacy of prednisolone 4mg\u002Fday added to standard of care in newly diagnosed rheumatoid arthritis (RA) patients with active disease.\n\nHypothesis Add-on prednisolone 4mg\u002Fday is efficacious compared to placebo in newly diagnosed RA patients with active disease.\n\nDesign and subjects This is a 12-week, randomized, placebo-controlled, double-blind study. We plan to enroll 112 adult patients with newly diagnosed active RA (Disease Activity Score 28-C-Reactive Protein \\[DAS28-CRP\\] \\> 3.2). They will be randomized 1:1 to receive prednisolone 4mg once daily for 5 weeks then tapering at 1mg\u002Fweek each week till off or placebo. Conventional synthetic disease-modifying-anti-rheumatic-drugs (DMARDs) will be started and adjusted according to a standard protocol aiming to achieve low disease activity. Patients with contra-indications to prednisolone, or requiring biologic or targeted synthetic DMARDs will be excluded.\n\nStudy instruments Clinical response will be monitored using DAS28-CRP every 4 weeks. Adverse events (AE), severe AE (SAE) and AE of special interest (AESI) will be recorded at every visit.\n\nMain outcome measures and analysis The primary outcome is the change of DAS28-CRP comparing the two groups at week-4 by student T test. Secondary outcomes include the changes of DAS28-CRP at week-8 and week-12 as well as proportion of patients with AE comparing the two groups. Independent factors predicting disease control will be analyzed by multivariate logistic regression.",[27],"2025-11-25",{"date":142,"type":32},"2025-12-02",{"date":144,"type":21},"2025-12-01",{"date":146,"type":21},"2028-06-30",{"name":148,"class":78},"Chinese University of Hong Kong",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100561732","la-function-and-dimensions-as-predictors-of-disease-activity-in-ra-100561732","NCT06593990","LA Function and Dimensions As Predictors of Disease Activity in RA","Left Atrial Function and Dimensions As Predictors of Disease Activity in Rheumatoid Arthritis Patients","Inclusion Criteria:\n\n\\- 1- Patients with RA (aged \\>18 years and duration of RA disease \\>1 year) come to the rheumatology\u002F Internal medicine department or outpatient clinics at Assiut University Hospital.\n\n2-RA are diagnosed based on the ACR\u002FEULAR 2010 rheumatoid arthritis classification criteria if a total score of ≥6 is needed to classify a patient as having definite RA\n\nExclusion Criteria:\n\n1. Patients with known history of atherosclerotic heart disease.\n2. Patients with overlap syndrome.\n3. Patients with hypothyroidism, Cushing's syndrome, anemia, and severe hepatic or renal dysfunction",{"count":157,"type":21},108,"the aim of this study is to\n\n* describe subclinical echocardiographic changes of the LA (dimensions and function) in patients with rheumatoid arthritis.\n* evaluate the correlation between Rheumatoid arthritis activity and subclinical structural changes of LA.\n* determine the association of LA volume index and atrial fibrillation or HFpf in RA patients.\n* apply Musculoskeletal Ultrasound detected synovitis to be correlated with cardiac function.",[27],[161,162,163,164],"left atrial function","rhematoid arthritis","musculoskeletal ultrasound","echocardiographic changes in rhematoid arthritis","2024-09-10",{"date":167,"type":32},"2024-09-19",{"date":169,"type":21},"2024-12-01",{"date":171,"type":21},"2026-01-01",{"name":173,"class":78},"Assiut University"]